Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.54 |
| ▸ | MIF | P14174 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606467 | 1.00 | ABCG2 (0.54) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL2409609 | 0.85 | ABCG2 (0.47) | ABCG2CA1CA2ALDH1A1MEN1 | |
| SCHEMBL5606965 | 0.84 | ABCG2 (0.61) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL5606962 | 0.84 | ABCG2 (0.61) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL5606934 | 0.83 | CA12 (0.48) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL5606938 | 0.83 | CA12 (0.48) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL5607374 | 0.81 | ALDH1A1 (0.45) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL5607378 | 0.81 | ALDH1A1 (0.45) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL5606469 | 0.80 | ALDH1A1 (0.50) | ABCG2MIFCA1CA2CA12 | |
| SCHEMBL11042783 | 0.80 | ABCG2 (0.56) | ABCG2MIFCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1687250-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | Takasago International Corporation (JP) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051882-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-(4-HYDROXYPHENYL)PROPIONIC ACIDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142472-A1 | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids | ALDH1A2, ALDH1A3, GRHPR | ABCG2 3631/4885MIF 2713/4885CA1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.